Phase 3 ADAURA Study Highlights Role for Precision Medicine in EGFR-Positive NSCLC
Masahiro Tsuboi, MD, discusses the findings from the phase 3 ADAURA clinical trial of osimertinib as treatment of patients with EGFR-mutated non–small cell lung cancer.
Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses the findings from the phase 3 ADAURA clinical trial of osimertinib (Tagrisso) as treatment of patients with EGFR-mutated non–small cell lung cancer (NSCLC).
In terms of safety, the adverse event (AE) profile was consistent with the known profile of osimertinib, the EGFR tyrosine kinase inhibitor. The most common AEs were primarily grades 1 or 2, and the incidence of grade 3 AEs was low with osimertinib, according to Tsuboi.
Osimertinib induced a highly significant and clinically meaningful improvement in disease-free survival and reduced the risk of distant recurrence. The disease-free survival was especially notable in the population of patients with completed resected stage 1/2b/3a EGFR-mutant NSCLC. Tsuboi says he has observed a wave if precision medicine in the post-operative space.
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
